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Abstract 
 
Objective:  The objective of this systematic review is to determine whether or not 
monotherapy treatment of etanercept is effective against plaque psoriasis. 
 
Study Design:  Review of three English language primary randomized controlled trials 
published 2007-2008. 
 
Data Sources:  Randomized, controlled clinical trials comparing etanercept to a control 
group were found using OVID, MEDLINE, and Cochrane database.   
 
Outcome Measured:  Disease improvement and Adverse Effects (headache).  Disease 
improvement was measured using the Physician’s Global Assessment (0=clear, 5=severe) 
and the Psoriasis Area and Severity Index (0 = no disease, 72 = maximal disease).  
Adverse effects (headache) were measured using the Common Toxicity Criteria of the 
National Cancer Institute. 
 
Results:  Three randomized controlled trials were included in this review.  Etanercept 50 
mg QW (van de Kerkhof et al) demonstrated greater efficacy than 50 mg BIW (Tyring et 
al and Moore et al) when etanercept was shown to improve plaque psoriasis.  Although 
the incidence of adverse effects was not frequent, headache was more commonly 
experienced in the etanercept group than the control group. 
 
Conclusion:  The results of the randomized controlled trials reviewed demonstrated that 
etanercept 50 mg QW was more effective than 50 mg BIW in improving plaque psoriasis.  
This should continue to be used as the starting dose in the treatment of plaque psoriasis.  
The relative low incidence of adverse effects encourages its use in treating plaque 
psoriasis.  Further studies should be done accounting for patient compliance in 
administering the drug. 
 
Key Words:  Plaque Psoriasis, Etanercept, Enbrel 
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Introduction 
 
 Plaque psoriasis is the most common type of psoriasis, affecting approximately 1-5% of 
the population in the United States.
1
  It commonly affects individuals from 16-22 years and again 
from 57-60 years.  Plaque psoriasis is a papulosquamous disease defined by erythematous 
plaques with a silvery scales.  These patches typically involve the extensor surfaces (elbows and 
knees), lower back, scalp, and nails.
2
  The impact of psoriasis on patient’s lives is substantial, 
including potential inability to work, discrimination, financial burden, and depression.
1
  Cost for 
patients to treat plaque psoriasis varies depending on disease severity.  Topical treatments range 
from $9 to $354.  Biologic therapies range from $8,400 to $22,112.  The cost of etanercept is 
$20,700 (60 doses) for one year of continuous treatment.
3
   
 Treatment of plaque psoriasis focuses on the improvement of the plaques not the 
disappearance of them due to its chronic nature.  The most effective treatment initially is the 
combination of steroids and calcipotriene, a vitamin D derivative.  However steroids must be 
used intermittently due to their side effects.   If the psoriasis is limited to the scalp, first line 
management is antidandruff shampoo.  If patients do not respond to these treatments or have 
plaques that cover more than 20% of their body surface area, then light and systemic therapy is 
recommended.  Light therapy involves UVB phototherapy and ultraviolet A (UVA) 
photochemotherapy.  Systemic medications include retinoids, methotrexate, cyclosporine, 
hydroxyurea, and immunomodulator drugs (i.e. etanercept).
3
 
 Plaque psoriasis is a T cell- mediated autoimmune disorder.  Plaques occur due to T cells 
attacking healthy skin cells by mistake.  The process begins when an environmental factor 
induces T cells to produce cytokines.  Cytokines stimulate keratinocyte proliferation and 
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production of antigenic adhesion molecules in the dermal blood vessels.  These molecules further 
stimulate T cells to produce cytokines, keeping the cycle going.
3
  
 As described above, plaque psoriasis is an immune-mediated dermatologic condition.  It 
has often been associated with increased levels of TNF, a proinflammatory cytokine, concluding 
that a TNF inhibitor would be most effective in treating plaque psoriasis.
1
  Etanercept is a 
soluble TNF receptor that has be approved by the FDA for treatment of various inflammatory 
disorders, including moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, ankylosing 
spondylitis, and moderate to severe plaque psoriasis.
1
 
Objective 
 
 The objective of this systematic review was to determine whether or not “Is monotherapy 
treatment of etanercept effective against plaque psoriasis?”.  Recent studies have suggested that 
etanercept may be safer and more effective than other drugs currently being used. 
Methods 
 
 All three trials used met the following criteria.  Participants had to be age > 18 years of 
age with stable, active psoriasis covering  10% of body surface area.  The intervention used was 
subcutaneous injections of etanercept.  The treatment group receiving etanercept injections were 
compared to those receiving a control treatment.  Outcomes measured were the reduction in 
disease severity and adverse effects (headache), which are patient oriented evidence that matters 
(POEM).  The types of studies used were the randomized controlled trials. 
 Tyring et al randomly assigned patients to receive subcutaneous injections of placebo or 
50 mg of etanercept BIW for first 12 weeks.  After the 12 weeks, all continuing patients received 
50 mg etanercept BIW in an open-label fashion.  Patients were trained on giving the injections at 
home.
4
  Moore et al had two groups, continuous and interrupted therapy that were randomly 
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assigned.  During the first 12 weeks, all patients received 50 mg twice weekly.  The continuous 
group received 50 mg QW for an additional 12 weeks.  At week 12, responders in the interrupted 
group discontinued therapy and upon relapse reinitiated treatment.
5
  Van de Kerkhof et al 
assigned patients to receive subcutaneous injections of placebo or 50 mg etanercept QW for 12 
weeks, in this double blind phase study.  After 12 weeks, all patients entered an open-label phase 
until 24 weeks.
1
 
 Key words used in the literature search were plaque psoriasis, Etanercept, and Enbrel.  
All articles were published in the English language in peer review journals after the year of 2005.  
Literature searches occurred via OVID and Medline using Cochrane databases.  Articles were 
selected based on importance of outcomes to the patient (POEMS).  Studies that were included 
were those that were randomized, controlled and based on patient oriented outcome.  Those 
excluded were studies that included patients under the age of 18 and body surface index ≤ 10%.  
Statistics utilized in these studies was p-values, relative risk reduction (RRR), absolute risk 
reduction (ARR), numbers needed to treat (NNT), and numbers needed to harm (NNH).   
 Outcomes measures were those of patient oriented evidence that matters.  Disease 
improvement was measured using the Physician’s Global Assessment (0 = clear, 5 = severe); and 
Psoriasis Area and Severity Index (0 = no disease, 72 = maximal disease).  Adverse effects 
(headache) were measured using the Common Toxicity Criteria of the National Cancer Institute.   
Table 1 demonstrates the demographics included in the studies. 
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Table 1: Characteristics of Studies Included for Analysis of Etanercept in the Treatment Of 
Plaque Psoriasis 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Tyring, 2007 (4) Randomized, 
double blind, 
controlled 
618 Mean 
age = 
45.6 
-At least 18 years of 
age 
-Active, stable plaque 
psoriasis involving  
10% of the body 
surface area (BSA) 
-Minimum PASI 
score of 10 
-Received at least 1 
previous 
phototherapy or 
systemic therapy or 
was a candidate  
-Adequate 
hematologic, renal, 
and hepatic function 
 
-History of psychiatric 
disease that would 
interfere 
-Skin conditions other 
than psoriasis that would 
interfere 
-Had active gestate, 
erythrodermic, and 
pustular psoriasis 
screening 
-Can not have received 
psoriasis therapy or 
PUVA for 4 weeks 
before, corticosteroids 2 
weeks before, or 
immunomodulators any 
time 
154 - Efficacy of 
50 mg of 
Etanercept 
BIW for 12 
weeks vs. 
Placebo 
- Safety of 50 
mg of 
Etanercept 
BIW for 12 
weeks vs. 
Placebo 
 
Moore, 2007 (5) Randomized, 
open-label 
2546 Mean 
age = 
45.4 
-Pts 18 years or older 
with stable, active 
plaque psoriasis 
involving  10% 
BSA 
-Any grade 3 or 4 adverse 
event or infection within 
28 days before screening, 
or between screening and 
study drug initiation 
-Other skin conditions 
that would interfere 
-PUVA, oral retinoids, 
alefacept, or anthralin 
within 14 days of drug 
initiation 
-Prior exposure to TNF 
inhibitor 
-History of TB 
345 -Interrupted 
therapy of 
etanercept 50 
mg BIW (over 
24 weeks) vs. 
Continuous 
therapy of 50 
mg BIW (over 
24 weeks) 
- Safety of 
interrupted 
therapy of 
etanercept 50 
mg BIW vs. 
continuous 
therapy of 50 
mg BIW 
 
Van de 
Kirchhoff, 2008 
(1) 
Randomized, 
double blind, 
controlled 
142 31-58 -Adult with stable 
plaque psoriasis 
involving  10% 
BSA 
-Minimum PASI 
score of 10 
-Failed to respond to 
at least one systemic 
of phototherapy 
-Pts with active guttate, 
erythrodermic or pustular 
psoriasis 
-Pts with serious infection 
within 1 month of study 
or BMI greater than 38 
-Pts that received a TNF 
inhibitor 
-No PUVA within 1 
month, no corticosteroids 
within 2 weeks 
20 - Safety of 
Etanercept 50 
mg QW vs. 
Placebo 
-Efficacy of 
Etanercept 50 
mg QW vs. 
Placebo 
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Results 
 
 The results were presented in dichotomous form in all three studies that were analyzed.  
Tyring et al demonstrated 51.1% in the etanercept group and 51.6% in the placebo group 
achieved a 75% improvement (PASI 75) in their plaque psoriasis.  The test is statistically 
significant (P < 0.001).  The relative benefit increase (RBI) was calculated to be -0.001 and the 
absolute benefit increase (ABI) was -0.01.  This study determined that the number needed to 
treat (NNT) was -100 for the treatment of etanercept 50 mg BIW (Table 2). 
 Moore et al. showed that 59.5% of participants in the etanercept group and 71.0% of 
those in the control group showed a response in their PGA score.  The test was seen to be 
statistically significant (P < 0.0001).  The absolute benefit increase was shown to be -0.115 and 
the relative benefit increase was -0.162.  NNT was determined to be -9 for those receiving 50 mg 
QW (Table 2). 
Van de Kerkhof et al. demonstrated that 71.1% of those in the etanercept group and 44.4% of 
those in the control group had a 75% improvement (PASI 75) in their plaque psoriasis.  The test 
was statistically significant (p < 0.0001).  The RBI was calculated to be 0.60 and the ABI was 
shown to be 0.266.  NNT for the study was found to be 4 patients at a dose of 50 mg QW (Table 
2).  
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Table 2: Efficacy of Etanercept on Improving Plaque Psoriasis 
Study Responders in 
the Etanercept 
group 
Responders 
in the control 
group 
P-value RBI ABI NNT 
Tyring (2007) 155/304 
(51.1%) 
148/287 
(51.6%) 
P < 0.001 -0.001 -0.01 -100* 
Moore (2007) 758/1274 
(59.5%) 
903/1272 
(71.0%) 
P < 0.0001 -0.162 -0.115 -9* 
Van de 
Kerkhof 
(2008) 
64/90 (71.1%) 16/36 
(44.4%) 
P < 0.0001 0.60 0.266 4 
RBI = Relative Benefit Increase   ABI = Absolute Benefit Increase   NNT = Numbers 
Needed to Treat 
*Since outcome measured was improvement of plaque psoriasis, the negative value for 
NNT indicates that for every 100/9 participants who took etanercept, there was one fewer 
who would have improvement in plaque psoriasis than in the group of participants taking 
the placebo. 
 
 There appears to be an inverse relationship related to the dosage of etanercept received 
and the numbers needed to treat.  Studies that received 50 mg BIW (Tyring et al and Moore et al) 
demonstrated negative values, as opposed to those receiving 50 mg QW who exhibited positive 
values.   
 One of the most common treatment emergent adverse effects experienced in all three 
studies was that of headache.  Headaches were typically mild and resolved in a day.  Headache 
was reported in 5.8%, 6.0%, and 13.5% of patients in the etanercept group for the studies Tyring 
et al, Moore et al, and van de Kerkhof et al respectively (Table 3).
1,4,5
  Headaches were typically 
more common in the etanercept group than the control group. This was not seen in Tyring et al, 
which demonstrated a numbers needed to harm (NNH) as a negative value.    
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Table 3: Incidences of Headache in Etanercept and Control groups 
Study Incidences of 
headache in 
Etanercept 
group 
Incidences of 
headache in 
control group 
P-value RRI ARI NNH 
Tyring (2007) 9.2/158.0 
(5.8%) 
36.4/418.8 
(8.7%) 
NR -0.747 -0.272 -4* 
Moore (2007) 76/1274 
(6.0%) 
61/1272 
(4.8%) 
NR 0.25 0.012 83 
Van de 
Kerkhof 
(2008) 
13/66 (13.5%) 1/46 (2.2%) P ≤ 0.05 5.14 0.113 8 
RRI = Relative Risk Increase   ARI = Absolute Risk Increase    NNH = Numbers Need to 
Harm 
*Outcome measured was incidence of headache, so this negative value means that for 
every 4 participants, one more participant will report the adverse effect of headache than 
if they received etanercept. 
 
 
Discussion 
 
The Randomized Controlled Trials on the study of the efficacy and safety of etanercept 
on treatment of plaque psoriasis demonstrated that 50 mg twice weekly (Tyring et al and Moore 
et al) was not as effective as 50 mg once weekly (van de Kerkhof et al).  Taking a closer look at 
the study of Moore et al, we see that the control group consisted of those patients receiving 
continuous therapy versus the experimental group, which received interrupted therapy.  This 
signified that although continuous therapy was more effective, that treatment of etanercept could 
be stopped and restarted and patients would still see improvement.  The treatment of 50 mg QW 
was shown to be highly efficacious and is currently the recommended starting dose for 
etanercept in the treatment of plaque psoriasis.  
 Etanercept was generally well tolerated by participants, showing the drug to be safe in the 
treatment of plaque psoriasis.  One of the most common adverse effects was that of headache, 
affecting the etanercept group more often.  However, similar frequency of headache was seen 
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between the etanercept groups and the control groups.  This suggests that headache may not have 
been related to drug use. 
Conclusion 
 
 Etanercept, a TNF inhibitor, was shown to be effective and safe in the treatment of 
plaque psoriasis.  While the results were not overwhelming convincing, it was demonstrated that 
the current recommended starting dose of 50 mg QW showed greater improvement.  We can also 
conclude that etanercept was effective when administered continuously or after discontinuation 
and re-treatment.  Although greater benefit was seen with continuous treatment, patients can re-
initiate treatment and expect similar response and without increased safety risk.
5
  Overall, 
etanercept demonstrated low numbers of treatment emergent adverse effects indicating it to be a 
relatively safe and tolerable drug.  Examining the methods used, limitations of the studies 
suggest that lack of high response seen may be due to noncompliance with etanercept 
administration or psoriasis-specific factors that decrease TNF dependency of the disease in 
patients treated with TNF antagonists.
1
  Future studies should eliminate noncompliance ad well 
as identify the psoriasis-specific factors that could affect the outcome.  Etanercept should 
continue to be used at 50 mg QW effectively and safely as statistically significantly 
demonstrated by these three studies. 
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